



April 25, 2024
JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Personnel Change

April 25, 2024 -- [JCR Pharmaceuticals Co., Ltd.](http://www.jcrpharm.co.jp/en/site/en/) (TSE 4552; Chairman and President: Shin Ashida; "JCR") hereby announces that its Board of Directors resolved at a meeting held today to change personnel change as follows.

1. Change of Corporate Officer (As of June 26, 2024)

Name	New Title	Current Title
Anne Bechet	Senior Corporate Officer, Executive Director, Clinical Development, General Manager, JCR Europe B.V., Director, JCR Luxemburg S.A and CEO, JCR USA Inc.	Clinical Development (Acting Officer), General Manager, JCR Europe B.V. and Director, JCR Luxemburg S.A.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 49-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products News Release in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler Scheie and Scheie syndrome), MPS II (Hunter syndrome), MPS III A and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com

###